Phio Pharmaceuticals

PHIOPhase 1

Phio Pharmaceuticals leverages its proprietary INTASYL self-delivering siRNA technology to develop next-generation immuno-oncology therapeutics. Co-founded by Nobel laureate Craig Mello, the company is advancing a clinical-stage pipeline targeting proteins like PD-1 and BRD4 to enhance anti-tumor immunity. With a strategic pivot from discovery to development under new leadership, Phio is focused on key initiatives in cutaneous squamous cell carcinoma and melanoma, aiming to overcome limitations of current immunotherapies.

Market Cap

$1.5B

Focus

RNA & Gene Therapy

PHIO · Stock Price

USD 128.5215553.08 (-99.18%)

Historical price data

AI Company Overview

Technology Platform

INTASYL self-delivering siRNA platform for precise gene silencing within immune and tumor cells without the need for complex delivery vehicles.

Pipeline Snapshot

2 drugs in pipeline

Drug	Indication	Stage
DP CD8 TIL + DP CD8 TIL KD + Low dose IL-2	HNSCC	Phase 1
PH-762	Squamous Cell Carcinoma of the Skin	Phase 1

Funding History

Total raised: $19M

PIPE$4MUndisclosedDec 15, 2020

IPO$10MUndisclosedOct 15, 2018

Series A$5MUndisclosedJun 15, 2012

Opportunities

Major opportunities include demonstrating clinical proof-of-concept for the INTASYL platform in immuno-oncology, which could unlock partnerships with larger pharma companies.

The platform's application to enhance cell therapies (CAR-T, TCR-T) represents a high-growth adjacent market.

Success in early trials could lead to expansion into additional solid tumor indications.

Risk Factors

Key risks include clinical failure of lead candidate PH-762, inability of the INTASYL platform to achieve effective gene silencing in human tumors, and severe financial constraints due to limited cash runway and low market valuation in a competitive capital environment.

Competitive Landscape

Phio competes with established RNAi companies (e.g., Alnylam, Arrowhead) focused on different diseases, and with large pharma developing small molecule inhibitors for targets like BRD4. Its differentiation lies in the self-delivering siRNA approach for transient, precise modulation of intracellular immuno-oncology targets directly within immune cells.